Literature DB >> 1983822

Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat.

D M Heuman1, A S Mills, J McCall, P B Hylemon, W M Pandak, Z R Vlahcevic.   

Abstract

The protective effect of ursodeoxycholate conjugates against bile salt hepatotoxicity was studied in chronic bile fistula rats. Taurochenodeoxycholate or taurodeoxycholate, infused intraduodenally at 24 or 16 mumols/100 g rat per hour, respectively, caused cholestasis and severe hepatocellular necrosis within 8 hours. In contrast, tauroursodeoxycholate or taurocholate at 48 mumols/100 g rat per hour were choleretic. Tauroursodeoxycholate was not hepatotoxic, whereas taurocholate produced moderate hepatocellular necrosis. Simultaneous infusion of tauroursodeoxycholate to rats receiving taurochenoxycholate or taurodeoxycholate preserved bile flow and ameliorated hepatic injury in a dose-dependent manner. Tauroursodeoxycholate protected equally by intravenous and intraduodenal routes. Intravenous glycoursodeoxycholate also was protective. The hydrophobicity index of infused bile salts correlated well with their toxicity. Concurrent administration of ursodeoxycholate conjugates did not reduce biliary recovery of intraduodenally infused [24-14C]-taurocholate. Biliary alkaline phosphatase secretion was stimulated by infusion of taurocholate, taurodeoxycholate, or taurochenodeoxycholate; simultaneous infusion of ursodeoxycholate conjugates failed to prevent this increase. We conclude that ursodeoxycholate counteracts hepatoxicity of more hydrophobic bile salts via a direct effect at the level of the liver.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1983822     DOI: 10.1016/0016-5085(91)90602-h

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  36 in total

1.  Acute effects of cholestatic and choleretic bile salts on vasopressin- and glucagon-induced hepato-biliary calcium fluxes in the perfused rat liver.

Authors:  Y Hamada; A Karjalainen; B A Setchell; J E Millard; F L Bygrave
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

Review 2.  Ursodeoxycholic acid in the treatment of liver diseases.

Authors:  S Saksena; R K Tandon
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

3.  Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production.

Authors:  C M Rodrigues; G Fan; P Y Wong; B T Kren; C J Steer
Journal:  Mol Med       Date:  1998-03       Impact factor: 6.354

4.  Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials.

Authors:  Mario Simental-Mendía; Adriana Sánchez-García; Luis E Simental-Mendía
Journal:  Br J Clin Pharmacol       Date:  2020-04-27       Impact factor: 4.335

Review 5.  Ursodeoxycholic acid treatment of vanishing bile duct syndromes.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

6.  Bile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the Long-Evans Cinnamon rat model.

Authors:  Brigid Joseph; Sorabh Kapoor; Michael L Schilsky; Sanjeev Gupta
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

7.  Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat.

Authors:  E E Frezza; G E Gerunda; M Plebani; A Galligioni; A Giacomini; D Neri; A M Faccioli; C Tiribelli
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

8.  Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.

Authors:  S Güldütuna; M Leuschner; N Wunderlich; A Nickel; S Bhatti; K Hübner; U Leuschner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Hepatoprotection with tauroursodeoxycholate and beta muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways.

Authors:  P Milkiewicz; M G Roma; E Elias; R Coleman
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

10.  Lithocholate-3-O-glucuronide-induced cholestasis. A study with congenital hyperbilirubinemic rats and effects of ursodeoxycholate conjugates.

Authors:  H Takikawa; K Minagawa; N Sano; M Yamanaka
Journal:  Dig Dis Sci       Date:  1993-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.